Efficacy and Safety of 0.25% Timolol Gel in Enhancing Full Thickness Skin Grafts Healing and Cosmetic Outcomes

• Status: Recruiting
• Trial end date: 2022-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 82 patients who have their skin cancer surgically removed resulting in the need of a full-thickness skin graft. The objective of this randomized safety study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in full-thickness skin grafts compared to standard of care.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Treatments: Petrolatum; Timolol

Criteria

Inclusion Criteria:

1. Age ≥18 years of age

2. Undergoing a procedure which results in the need of a FTSG

3. Willing to provide written informed consent

Exclusion Criteria:

1. Age less than 18 years of age

2. Pregnant women

3. (Use of systemic drugs that can impede wound healing, such retinoids or immune-suppressive drugs)

4. Severe coagulation disorders

5. Severe, uncontrolled systemic comorbidities, such as diabetes, arthritis, etc.

6. Hypersensitivity to 0.25% timolol gel

7. Not willing to provide written informed consent